Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Towards defining the Parkinson’s health-ome
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
174
To determine which environmental exposures or risk factors are enriched in patients with Parkinson’s disease (PD).
Many studies have examined the relation between PD, health data, and environmental variables serially --- one association at a time. In the real world however, both environmental exposures and patients are much more complex, including phenotypic diversity, complex comorbidities, and polypharmacy. Here we begin to characterize a holistic picture of environmental, clinical, and pharmacological traits linked to patients with PD.
The Harvard Biomarkers Study (HBS) is a large cohort of PD patients and healthy controls that includes an extensive environmental exposure and past medical and social history dataset, and it is thus well-suited for such an exploratory study. We performed a logistic regression with backward elimination to predict PD, initially examining 63 environmental exposures or risk factors in the HBS. We performed factor analysis using variables from the categories of past medical history, medication use, supplement use, social history, and environmental exposures, in order to uncover latent associations between individual variables in different categories. We then repeated the logistic regression with the identified factors.
Logistic regression analysis identified male sex, depression, anxiety, restless leg syndrome, head trauma, ibuprofen use, co-enzyme Q10 use, and vitamin D as positively enriched in PD patients and asthma/chronic obstructive pulmonary disease (COPD), naproxen use, lansoprazole use, and smoking as under-represented in PD patients. Factor analysis revealed three latent variables underlying these associations: a cardiovascular disease factor, a psychiatric disease factor, and a vitamin use factor.  
This study provides a holistic look at the comprehensive “health-ome” of PD, both confirming associations that have been previously reported as well as pointing at novel insights. 
Authors/Disclosures
Abby L. Olsen, MD (University of Pittsburgh)
PRESENTER 		An immediate family member of Dr. Olsen has received personal compensation for serving as an employee of Rheos Medicines. An immediate family member of Dr. Olsen has received personal compensation for serving as an employee of Novasenta. An immediate family member of Dr. Olsen has received personal compensation for serving as an employee of Biohaven. The institution of Dr. Olsen has received research support from NINDS. The institution of Dr. Olsen has received research support from DoD. The institution of Dr. Olsen has received research support from American Parkinson's Disease Association. The institution of Dr. Olsen has received research support from Alzheimer's Association.
No disclosure on file
Clemens R. Scherzer, MD (Yale) Dr. Scherzer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Scherzer has received research support from NIH. The institution of Dr. Scherzer has received research support from Michael J. Fox Foundation. The institution of Dr. Scherzer has received research support from American Parkinson's Disease Association. Dr. Scherzer has received intellectual property interests from a discovery or technology relating to health care.